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1220Left Main Coronary Artery Stenosis
A Meta-Analysis of Drug-Eluting Stents Versus Coronary Artery Bypass GraftingObjectives The goal of this study was to provide a systematic review comparing the long-term outcomes of percutaneous
coronary intervention (PCI) with drug-eluting stents (DES) versus coronary artery bypass graft surgery (CABG) for unprotected left
main coronary artery (UPLM) stenosis.
Background One-year outcomes from randomized controlled trials, observational studies, and pooled analyses have demonstrated
the safety and efﬁcacy of PCI of the UPLM when compared with CABG. However, there remain concerns over the sustainability of
PCI with DES at longer follow-up.
Methods Studies published between January 2000 and December 2012 of PCI versus CABG for UPLM stenosis were identiﬁed
using an electronic search and reviewed using meta-analytical techniques.
Results Twenty-four studies comprising 14,203 patients were included in the analysis. There was no signiﬁcant difference for all-
cause mortality between PCI or CABG at 1 year (odds ratio [OR]: 0.792, 95% conﬁdence interval [CI]: 0.53 to 1.19), 2 years (OR: 0.920,
95% CI: 0.67 to 1.26), 3 years (OR: 0.94, 95% CI: 0.60 to 1.48), 4 years (OR: 0.84, 95% CI: 0.53 to 1.33), and 5 years (OR: 0.79, 95% CI:
0.57 to 1.08). The need for target vessel revascularization (TVR) was signiﬁcantly higher in patients undergoing PCI at all time points.
The occurrence of stroke, however, was signiﬁcantly less frequent in patients treated with PCI. The occurrence of nonfatal
myocardial infarction showed a statistically signiﬁcant trend towards a lower incidence in CABG patients at 1 year (OR: 1.62, 95% CI:
1.05 to 2.50), 2 years (OR: 1.60, 95% CI: 1.09 to 2.35), and 3 years (OR: 2.06, 95% CI: 1.36 to 3.1). There was no signiﬁcant difference in
combined major adverse cardiovascular and cerebrovascular events between the 2 groups.
Conclusions Our ﬁndings suggest that PCI with DES is a safe and durable alternative to CABG for the revascularization of UPLM
stenosis in select patients at long-term follow-up. (J Am Coll Cardiol Intv 2013;6:1219–30) ª 2013 by the American College of
Cardiology FoundationIn recent years, 12-month outcomes after percutaneous
coronary intervention (PCI) with drug-eluting stents (DES)
of the unprotected left main coronary artery (UPLM) have
consistently been shown to be noninferior to coronary artery
bypass graft surgery (CABG) (1,2). This has been reﬂected in
the current American College of Cardiology/American Heart
Association guidelines, with PCI of the UPLM being
upgraded from a Class III indication in 2006 to a Class IIb
indication in 2009 and to a Class IIa indication in 2011, when
anatomy is favorable for PCI and surgical risk is high (3).
Longer follow-up of the landmark SYNTAX (SynergySee page 1231Between Percutaneous Coronary Intervention With Taxus
and Cardiac Surgery) trial (4), however, has raised concerns
over the durability and safety of PCI over CABG in high-risk
lesions after early success. At 5 years (4), the difference
between surgery and stenting in the SYNTAX trial showed
a trend in favor of CABG for all-cause death (9.2% vs. 14.6%,
p ¼ 0.006), cardiac death (4.0% vs. 9.2%, p < 0.001), andmyocardial infarction (MI) (3.3% vs. 10.6%, p< 0.001). The
21 composite endpoint of death/stroke/MI was similarly less
frequent in patients undergoing CABG (14% vs. 22%, p <
0.001). Also observed was a slow catch-up for stroke risk, with
the difference in stroke that was initially signiﬁcant and in
favor of PCI (1) (0.6% vs. 2.2%) being no longer present (3.0%
vs. 3.4%, p ¼ 0.66) at 5 years. Outcomes in the left main
coronary artery subset at follow-up did not show this trend;
nonetheless, the study was underpowered for subset analyses.
Similar to in the SYNTAX trial, the early advantages of PCI
over CABG has been shown to progressively shift to CABG
over time in certain other coronary interventions (5). There are
also concerns over the long-term safety ofDES,with reference
to increased MI and death driven primarily by late and very
late stent thrombosis. We therefore undertook a systematic
review to compare the temporal and long-term outcomes of
CABG versus PCI withDES for UPLM stenosis (UPLMS).
Methods
Study selection. We conducted a systematic review of the
published data on CABG versus PCI with DES for UPLM
stenosis following QUOROM (Quality of Reporting of
Abbreviations
and Acronyms
CABG = coronary artery
bypass graft surgery
CI = conﬁdence interval
DES = drug-eluting stent(s)
IVUS = intravascular
ultrasound
MACCE = major adverse
cardiovascular and
cerebrovascular event(s)
MI = myocardial infarction
OR = odds ratio
PCI = percutaneous coronary
intervention
RCT = randomized controlled
trial
TVR = target vessel
revascularization
UPLM = unprotected left
main coronary artery
UPLMS = unprotected left
main coronary artery
stenosis
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1221Meta-Analyses) (6) and MOOSE (Meta-Analysis of Obser-
vational Studies in Epidemiology) guidelines (7). The authors
performed data collection from 3 online databases: Medline
(PubMed), Cochrane Collaboration of Clinical Trials, and
Google Scholar. The searches were limited by date and
extended from January 2000 to December 2012.
The primary search term used was “left main.” A
secondary search was carried out combining the term “left
main” with “CABG,” “PCI,” and “DES.” For the Cochrane
database, the search terms were limited by the term “clinical
trial.” We subsequently limited the search parameters to the
English language. The primary search term was also used in
various combinations with the secondary search terms to
retrieve relevant papers. We screened citations at the title
and abstract level, and retrieved papers as full reports if they
were clinical studies; we then compared PCI of the left main
coronary artery to CABG and provided information on the
outcomes. The full text of all potential papers were reviewed
in detail. The bibliographies of retained studies was used to
seek additional relevant studies.
Inclusion criteria. Studies were included if the following
criteria applied: 1) comparative trials (randomized controlled
trials [RCTs] and nonrandomized) of CABG versus PCI
with DES stent placement; 2) unprotected left main stenosis
of >50% narrowing; 3) minimum of 30 patients in the PCI
arm with at least 75% receiving DES; and 4) a minimum
follow-up of 1 year or more. When 2 similar studies were
reported from the same institution or author, the most
recent publication was included in the analysis. The 30-
patient threshold was selected to comprehensively identify
all available evidence on the use of DES versus CABG for
the UPLMS. The penetration rate of DES use in the U.S.
PCI population has been estimated to be around 76.9% (8).
We therefore included reports with 75% to 100% DES use
but studies with <75% DES use were excluded.
Exclusion criteria. Studies were excluded if any of the
following criteria applied: 1) duplicate publication; 2) lack
of minimum of 1-year follow-up; 3) outcomes of interest
were not clearly reported or were impossible to extract or
calculate from the published results; and 4) single-arm
studies.
Data extraction. The primary studies were reviewed multiple
times by both G.A. and E.P. to establish familiarity with the
ﬁndings. The items for data extraction, the data extraction
sheet, and the methodology for event count extraction were
then standardized before data collection. Information
collected included ﬁrst author, year and journal of publica-
tion, study design, inclusion/exclusion criteria, deﬁnition of
primary and secondary endpoints, number of subjects
included, subjects undergoing PCI and CABG, percentage
of DES used, study population demographics, left main
stenosis location (ostial, mid-shaft, or distal), number of
diseased vessels, stenting technique used to treat bifurcation
lesions, type of CABG (on pump vs. off pump), left internalmammary artery graft used (single vs. double), follow-up
time period, rates of angiographic follow-up, antiplatelet
regimen used, and primary and secondary outcomes.
Ignoring variable deﬁnitions, event counts for the primary
(death, MI, stroke, and percutaneous coronary intervention
[TVR]) and secondary outcomes (combined major adverse
cardiovascular and cerebrovascular events [MACCE]) were
extracted as reported by the individual studies. There was no
disagreement between the 2 reviewers (G.A. and E.P.).
Study endpoints. The primary endpoints were all-cause
mortality, TVR, stroke, and MI at all available time points.
Secondary endpoints were cardiac mortality and combined
MACCE: a composite of all-cause mortality, nonfatal MI,
and stroke.
Statistical analysis. A forest plot
with combined odds ratio (OR)
estimates and 95% conﬁdence
intervals (CIs) was constructed
using the random effects model of
DerSimonian and Laird (9).
Statistical signiﬁcance for OR was
set at p < 0.05 (2-tailed) provided
the CI did not cross 1. Heteroge-
neity, which was anticipated to be
signiﬁcant, was assessed by
a Q-statistic and I2 test. Signiﬁ-
cant heterogeneity was considered
present for p values <0.10 and/or
an I2 50%. Sensitivity analysis
was performed by performing: 1)
a separate analysis on adjusted
outcomes (RCTs, propensity-
matched, propensity score–
adjusted, or multivariate-
adjusted data); and 2) analysis on
the basis of the SYNTAX scores.
An assumption of ﬁxed propor-
tional hazards was made for this
analysis. Data analysis was per-
formed using Meta-analyst version 1.0 (10) and Compre-
hensive Meta-Analysis version 2.0 (Biostat, Englewood, New
Jersey) (11).
We conducted a random effects meta-regression analysis
using the method of moments to investigate the impact of
various study characteristics in the PCI arm on the study
estimates of ORs. The natural logarithm of the OR was the
dependent variable, and the number of participants, the
percentage of smokers, diabetic patients, distal left main
disease, isolated left main disease, left main and 3-vessel
disease, and intravascular ultrasound (IVUS) use were
entered as explanatory factors. The probability of obtaining
a spurious explanation for variable treatment effects is high
when a small number of studies are used, and we therefore
chose to perform the regression analysis on outcomes that
Table 1. Characteristics of Included Studies
First Author/Study
(Ref. #)* Year N DES CABG DM Distal LM EuroSCORE (PCI) EuroSCORE (CABG) SYNTAX (PCI) SYNTAX (CABG)
Morice et al. (1) 2008 705 357 348 25% 56% 3.9 þ 2.8 3.9  2.9 29.6  13.5 30.2  12.7
Boudriot et al. (2) 2011 201 100 101 36% 74% 2.4 (1.5–3.7) 2.6 (1.7–4.9) 24 (19–29) 23 (14.8–28)
Shimizu et al. (e1) 2010 152 63 89 47% d 2.7 (1.9–5.1) 4.9 (2.4–11.5) d d
Chieffo et al. (e2) 2006 249 107 142 21% 81% 4.4  3.6 4.3  3.4 28.8  10.4 29.4  5.78
CUSTOMIZE (e3) 2011 583 222 361 39% 52% 6.3  3.0 5.6  2.5 26.0  10.8 33.6  13.0
Ghenim et al. (e4) 2009 211 105 106 27% 74% 8 (6–9) 7 (6–8) d d
Makikallio et al. (e5) 2008 287 49 238 17% 80% 7.7  7.5 5.2  4.4 d d
Rittger et al. (e6) 2011 287 95 192 36% 64% d d d d
San Martin et al. (e7) 2007 341 96 245 28% 61% High ¼ 27% High ¼ 25.30% d d
Kawecki et al. (e8) 2012 145 34 111 28% 53% 4.76  3.36 4.81  2.67 d d
Luo et al. (e9) 2012 823 331 492 27% 75% 4 (3–6) 5 (4–7) d d
Palmerini et al. (e10) 2007 259 98 161 28% 89% 8 (4–18) 7 (3–14) d d
PRECOMBAT (e11) 2011 600 300 300 32% 67% 2.6  1.8 2.8  1.9 SES: 24.4  9.4 25.8  10.5
Zhao et al. (e12) 2011 172 56 116 87% 75% d d d d
Yi et al. (e13) 2012 512 243 269 36% 43% d d d d
Kang et al. (e14) 2010 462 205 257 41% 79% 4.2  3.9 5.6  3.8 d d
CREDO-Kyoto 2 (e15) 2012 1,005 365 640 44% 58% d d 26.5 (21–34) 30 (22–40)
DELTA registry (e16) 2012 2,774 1,874 900 30% 60% 4.9  3.6 5.1  2.6 28.6  14.3 38.9  13.2
ASAN (e17) 2010 395 176 219 34% 68% 3.3  2.7 4.5  2.6 d d
Wu et al. (e18) 2010 376 131 245 28% 68% 4.2  2.7 4.3  2.4 d d
Chang et al. (e19) 2012 865 556 309 35% 100% 3.8  2.5 4.2  2.3 25.3  10.2 34.5  14.1
Qin et al. (e20) 2012 515 233 282 26% 68% 3.7  2.3 4.5  2.6 24.1  10.5 34.5  12.0
Park registry (e21) 2011 810 475 335 38% 65% 3.1  2.2 3.7  2.1 22.5  9.9 37.8  11.9
MAIN-COMPARE (e22) 2008 1,474 784 690 34% 57% d d 24.8  10.9 38.7  13.3
Capodanno et al. (e23) 2011 556 285 271 28% 52% d d 20.1 6.3 22.8  6.1
Values are N, %, mean  SD, or median (interquartile range). *Reference numbers that begin with the letter e can be found in the Online Appendix.
ASAN ¼ Asan Medical Center-Multivessel Revascularization registry; CABG ¼ coronary artery bypass graft surgery; CREDO-Kyoto ¼ Coronary REvascularization Demonstrating Outcome study in Kyoto;
CUSTOMIZE ¼ Appraise a CUSTOMIZEd strategy for left main revascularization registry; DELTA ¼ Drug-Eluting Stent for Left Main Coronary Artery Disease; DES ¼ drug-eluting stents; DM ¼ diabetes
mellitus; LM ¼ left main coronary artery; MAIN-COMPARE ¼ revascularization for unprotected left MAIN coronary artery stenosis: COMparison of Percutaneous coronary Angioplasty versus surgical
Revascularization study; PCI ¼ percutaneous coronary intervention; PRECOMBAT ¼ Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with
Left Main Coronary Artery Disease trial; SES ¼ sirolimus-eluting stents.
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1222were reported by at least 90% of the studies. The studies were
grouped into early (1 to 2 years) and late (3, 4, and 5 years)
follow-up.Table 2. Overall Patient Demographics
PCI
(n ¼ 7,055)
CABG
(n ¼ 7,148) p Value
Age, yrs 63.9  9.1 66.9  7.9 >0.05
Male 5,576 (79.03) 5,458 (76.3) <0.05
Diabetes mellitus 2,415 (34.2) 2,582 (36.1) <0.05
Hypertension 4,812 (68.2) 4,725 (66.1) <0.05
Hypercholesterolemia 3,383 (47.9) 2,926 (40.9) <0.05
Smoking 2,536 (35.9) 2,435 (34.0) <0.05
Chronic kidney disease 415 (5.8) 352 (4.9) <0.05
Prior MI 763 (10.8) 976 (13.6) <0.05
Prior PCI 1,364 (19.3) 644 (0.09) <0.05
Values are mean  SD or n (%).
MI ¼ myocardial infarction; other abbreviations as in Table 1.Results
By using the search key words, 5,796 reports were identiﬁed,
of which 188 relevant publications were identiﬁed at the
abstract and title level. By applying the inclusion and exclu-
sion criteria, 24 reports were selected for the meta-analysis
(1,2) (Online Refs. e1–e22). These included 3 randomized
comparisons (1,2) (Online Ref. e11) and 21 nonrandomized
comparisons (Online Refs. e1–e10,e12–e22). Of the 21
nonrandomized comparisons, 16 studies provided adjusted
estimates by either propensity matching or propensity score
or multivariate adjustment to account for selection bias
(Online Refs. e2–e6,e9,e10,e12–e19,e22). All the studies
included in the analysis were published between 2006 and
2012. Analysis was performed on 14,203 patients, of
whom 7,055 (49.7%) underwent PCI with stenting and7,148 (50.3%) underwent CABG. The study characteristics
and overall patient demographics are shown in Tables 1
and 2, respectively. All the studies provided enough details
on the primary endpoints of all-cause mortality, stroke, and
TVR. Nonfatal MI was variably reported by the primary
Figure 1. Forest Plot of Mortality in PCI Versus CABG Patients for UPLMS
Forest plot showing the odds ratios for mortality in percutaneous coronary
intervention (PCI) versus coronary artery bypass graft surgery (CABG) patients
for unprotected left main coronary artery stenosis (UPLMS) after 1, 2 ,3, 4, and
5 years (years are indicated by the numbers on the left). DES ¼ drug-eluting
stent.
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1223studies. The deﬁnition of primary and secondary endpoints
by the individual studies was variable (Online Table 1). The
time-point analysis involved 14 studies on 1-year outcomes
(1,2) (Online Refs. e2–e8,e11,e14,e15,e18,e21), 10 on 2-year
outcomes (1) (Online Refs. e1,e9–e12,e14,e15,e18,e21), 6 on
3-year outcomes (OnlineRefs. e14,e15,e18,e20,e23,e24), 4 on
4-year outcomes (Online Refs. e16,e18,e22,e25), and 6 on
5-year outcomes (4) (Online Refs. e13,e17,e19,e26,e27).
There was no signiﬁcant difference in the incidence of all-
cause mortality (Fig. 1) between PCI and CABG at 1 year
(OR: 0.792, 95% CI: 0.53 to 1.19), 2 years (OR: 0.920, 95%
CI: 0.67 to 1.26), 3 years (OR: 0.94, 95% CI: 0.60 to 1.48),
4 years (OR: 0.84, 95% CI: 0.53 to 1.33), and 5 years (OR:
0.79, 95% CI: 0.57 to 1.08).
The need for TVR (Fig. 2) was signiﬁcantly higher in
patients undergoing PCI at 1 year (OR: 3.92, 95% CI: 2.87
to 5.34), 2 years (OR: 3.67, 95% CI: 2.61 to 5.18), 3 years
(OR: 3.45, 95%CI: 2.23 to 5.35), 4 years (OR: 2.73, 95%CI:
1.86 to 4.03), and 5 years (OR: 3.77, 95% CI: 2.43 to 5.87).
The occurrence of stroke (Fig. 3) was signiﬁcantly less
frequent in patients undergoing PCI at 1 year (OR: 0.54,
95% CI: 0.31 to 0.94), 2 years (OR: 0.56, 95% CI: 0.36 to
0.86), 3 years (OR: 0.56, 95% CI: 0.32 to 0.98), 4 years
(OR: 0.57, 95% CI: 0.38 to 0.86), and 5 years (OR: 0.27,
95% CI: 0.13 to 0.55).
There was a statistically signiﬁcant trend towards a higher
incidence of nonfatal MI (Fig. 4) in PCI patients at 1 year
(OR: 1.62, 95% CI: 1.05 to 2.50), 2 years (OR: 1.60, 95%
CI: 1.09 to 2.35), and 3 years (OR: 2.06, 95% CI: 1.36 to
3.1). The occurrence of nonfatal MI was similar between the
2 groups at 4 years (OR: 1.12, 95% CI: 0.75 to 1.68), and
5 years (OR: 1.38, 95% CI: 0.71 to 2.70).
MACCE at follow-up (Fig. 5) was not signiﬁcantly
different between the 2 groups at 1 year (OR: 0.93, 95% CI:
0.66 to 1.34), 2 years (OR: 1.01, 95% CI: 0.74 to 1.38),
3 years (OR: 1.15, 95% CI: 0.81 to 1.63), and 4 years
(OR: 0.83, 95% CI: 0.61 to 1.11). MACCE at 5 years was
signiﬁcantly lower in the PCI group (OR: 0.64, 95% CI:
0.51 to 0.80).
There was no signiﬁcant difference in the incidence
of cardiac mortality between PCI and CABG at 1 year
(OR: 1.19, 95% CI: 0.59 to 2.39), 2 years (OR: 1.02, 95%
CI: 0.54 to 1.89), 3 years (OR: 1.08, 95% CI: 0.37 to 3.11),
4 years (OR: 1.11, 95% CI: 0.81-1.52), and 5 years (OR:
0.95, 95% CI: 0.36 to 2.50).
We explored the robustness of our ﬁndings in sensitivity
analysis by: 1) performing an analysis on adjusted estimates
derived from studies on the basis of randomization, propensity
matching, propensity score adjustment, or multivariate
adjustment; and2) analysis on the basis of the SYNTAXscores.
In the subgroup analysis (Table 3) of studies reporting on
adjusted outcomes, there was no difference in all-cause
mortality and MACCE between the 2 groups as reported in
the primary analysis. TVR was higher in the PCI armdespite adjustments for confounding factors. Adjusted data
for stroke and MI were underreported and therefore could
not be adequately analyzed. The analysis was severely
restricted with loss of over two-thirds of the study
Figure 3. Forest Plot of Stroke in PCI Versus CABG Patients for UPLMS
Forest plot showing the odds ratios for stroke in PCI versus CABG patients for
UPLMS after 1, 2, 3, 4, and 5 years. Years are indicated by the numbers on the
left. Abbreviations as in Figure 1.
Figure 2. Forest Plot of TVR in PCI Versus CABG Patients for UPLMS
Forest plot showing the odds ratios for target vessel revascularization (TVR) in
PCI versus CABG patients for UPLMS after 1, 2, 3, 4, and 5 years. Years are
indicated by the numbers on the left. Abbreviations as in Figure 1.
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ability of these results.
Three studies stratiﬁed outcomes on the basis of the
angiographic SYNTAX score. In pooled analyses of these 3studies, the 3-year mortality (Fig. 6), MI, and MACCE
were not signiﬁcantly different with PCI compared with
those of CABG for the low and intermediate SYNTAX
scores. In patients with a high SYNTAX score, PCI was
unfavorable for mortality (OR: 1.62, 95% CI: 1.11 to 2.36,
Q ¼ 0.55, I2 ¼ 0.00), MI (OR: 2.53, 95% CI: 1.32 to 4.85,
Q ¼ 0.83, I2 ¼ 0.00), and MACCE (OR: 1.44, 95% CI:
1.01 to 2.06, Q ¼ 1.95, I2 ¼ 0.00). TVR was higher in all 3
subgroups. Stroke was not signiﬁcantly different between
PCI and CABG for any of the 3 subgroups.
The meta-regression analysis demonstrated an inverse
relationship between percentage of diabetic patients and
Figure 5. Forest Plot of MACCE in PCI Versus CABG Patients for UPLMS
Forest plot showing the odds ratios for major adverse cardiovascular and
cerebrovascular events (MACCE) in PCI versus CABG patients for UPLMS after
1, 2, 3, 4, and 5 years. Years are indicated by the numbers on the left.
Abbreviations as in Figure 1.
Figure 4. Forest Plot of MI in PCI Versus CABG patients for UPLMS
Forest plot showing the odds ratios for myocardial infarction (MI) in PCI versus
CABG patients for UPLMS after 1, 2, 3, 4, and 5 years. Years are indicated by
the numbers on the left. Abbreviations as in Figure 1.
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(Fig. 7), that is, diabetic patients were more prone to TVR
when treated by PCI with DES at long-term follow-up (p ¼
0.015). Meta-regression analysis did not disclose any other
statistically signiﬁcant relationship.
Discussion
Our review of over 24 studies, including 3 RCTs and a total
of 14,203 patients, is the largest meta-analysis on this topicon long-term follow-up, to our knowledge. Our ﬁndings
suggest that in select patients, PCI is a safe and durable
alternative to CABG at short-and long-term follow-up.
Previous meta-analyses on the same topic have been
limited to a 1-year follow-up (12,13) or have combined short
and longer lengths of follow-up (14). Contrasting PCI and
CABG outcomes at 1 year, though important, is not a fair
assessment because it adversely affects CABG by negating
its potential long-term advantage. With current medical
therapy and advances in both ﬁelds, a follow-up of at least
5 years would be necessary to detect signiﬁcant outcome
Table 3. Sensitivity Analysis: Pooled Analysis of Adjusted/Matched Outcomes in PCI Versus CABG Patients
for UPLMS
Time
Point
Pooled Analysis for
Hazard Ratios
Hazard Ratio
(95% CI)
Pooled Analysis
for Odds Ratios
Odds Ratio
(95% CI)
No. of
Studies
Sample
Size
No. of
Studies
Sample
Size
Mortality 1 year 4 1,533 0.46 (0.18–1.15) 3 1,506 0.81 (0.46–1.43)
2 year 5 2,230 0.66 (0.42–1.03) 2 1,305 0.82 (0.48–1.39)
3 year 4 3,317 0.91 (0.50–1.65) 1 705 0.86 (0.50–1.50)
4 year 2 3,150 0.66 (0.24–1.85) 1 705 1.03 (0.64–1.64)
5 year 3 2,734 1.18 (0.87–1.61) 3 1,210 0.96 (0.52–1.78)
TVR 1 year 3 1,246 6.50 (3.32–12.72) 4 1,755 2.17 (1.48–3.17)
2 year 4 1,971 3.34 (2.07–5.39) 2 1,305 1.94 (1.33–2.82)
3 year 4 3,317 4.88 (3.51–6.77) 1 705 1.86 (1.22–2.82)
4 year 2 3,150 2.72 (1.84–4.01) 1 705 1.79 (1.22–2.63)
5 year 3 2,734 5.76 (3.63–9.13) 3 1,210 3.13 (1.57–6.23)
MI 1 year 1 583 4.80 (0.32–72.58) 3 1,506 1.08 (0.58–2.01)
2 year 2 1,423 1.79 (0.76–4.20) 2 1,305 1.32 (0.71–2.46)
3 year 1 1,005 2.47 (0.81–7.54) 1 705 1.80 (0.92–3.52)
4 year NA NA NA 1 705 1.53 (0.81–2.87)
5 year NA NA NA 2 961 1.83 (0.99–3.34)
Stroke 1 year 1 287 0.38 (0.04–3.35) 2 1,305 0.12 (0.02–0.72)
2 year 2 1,423 0.64 (0.18–2.34) 2 1,305 0.26 (0.08–0.80)
3 year 1 1,005 0.79 (0.30–2.08) 1 705 0.27 (0.09–0.83)
4 year NA NA NA 1 705 0.31 (0.11–0.88)
5 year NA NA NA 2 961 0.42 (0.19–0.93)
MACCE (death/
MI/stroke)
1 year 1 376 0.45 (0.17–1.19) 5 1,966 0.61 (0.43–0.88)
2 year 3 1,799 0.91 (0.55–1.53) 2 1,305 0.84 (0.56–1.26)
3 year 5 3,873 1.04 (0.74–1.46) 1 705 0.88 (0.57–1.36)
4 year 2 3,150 0.73 (0.41–1.33) 1 705 0.95 (0.64–1.40)
5 year 3 2,734 1.16 (0.87–1.55) 2 954 0.69 (0.34–1.38)
CI ¼ conﬁdence interval; MACCE ¼ major adverse cardiovascular and cerebrovascular events; NA ¼ not available; TVR ¼ target vessel revas-
cularization; UPLMS ¼ unprotected left main coronary artery stenosis; other abbreviations as in Tables 1 and 2.
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1226differences. Similarly, given the potential for treatment
effect sizes to diverge over time, combining short and longer
lengths of follow-up may be misleading. Analyzing out-
comes over varied follow-ups separately, therefore, appears
worthwhile. Importantly our meta-analysis involves close to
4,000 patients at each separate time point and is more
inclusive of the DES data that are currently available.
The absence of a survival beneﬁt with CABG even at 5
years from the index procedure, a time period in which
a portion of the beneﬁt from CABG may have accrued,
suggests that the increased rate of TVR in the PCI arm
is not translating into increased mortality as compared
with CABG. In other words, there is a similar short-and
long-term risk of mortality between the 2 procedures. In
our analysis, ﬁrst-generation DES were predominantly
used. First-generation DES are associated with increased
risk of very late stent thrombosis occurring >1 year after
stent implantation (15). Despite this increased risk, our
analysis shows an equivalence of PCI with DES ascompared with CABG for the outcome of mortality up
to 5 years.
Strokes are signiﬁcantly reduced in patients undergoing
PCI at follow-up and do not support concerns raised by the
SYNTAX trial of a late catch-up of strokes in the PCI arm
(4) (Online Refs. e24,e25). Our result is also in line with
that of Capodanno et al. (12), who reported an increased
risk of stroke in patients undergoing CABG. The risk of
stroke with CABG is therefore real and should be factored
in determining the choice of therapy for an individual
patient.
In our overall analysis, nonfatal MI showed a trend in
favor of CABG that was statistically signiﬁcant. This ﬁnding
has not been observed in prior meta-analyses. The result,
however, must be interpreted with some caution as the
sensitivity models to test the inﬂuence of unadjusted
comparisons were underpowered to conﬁrm it. Nevertheless,
the risk of MI after PCI needs to be taken seriously in lieu of
the risk of very late stent thrombosis and signals from RCTs
Figure 6. Forest Plots of Mortality, MI, MACCE, and TVR in PCI Versus CABG Patients for UPLMS
Forest plot showing the odds ratios for (A) mortality, (B) MI, (C) MACCE, and (D) TVR in PCI versus CABG patients for UPLMS. Groups are stratiﬁed by the SYNTAX score
into low, intermediate, and high score groups. Abbreviations as in Figures 1 to 5.
Figure 7. Plot of Univariate Meta-Regression Examining the Effect of DM on the Relationship Between PCI and TVR
Plot of univariate meta-regression examining the effect of diabetes (DM) on the relationship between PCI and TVR (p ¼ 0.015). Abbreviations as in Figure 1.
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1228and observational studies of increased MI among PCI-
treated patients (4,5,16). In the FREEDOM (Future
Revascularization Evaluation in Patients with Diabetes
Mellitus: Optimal Management of Multivessel Disease) trial
(5), 1,900 diabetic patients with multivessel disease were
randomized to receive either PCI with DES or CABG.
Over a median follow-up of 3.8 years, MI occurred more
frequently in patients undergoing PCI with DES when
compared with CABG (13.9% vs. 6%, p < 0.001).
The ﬁnding of increased risk of TVR with PCI with
DES than with CABG came as no surprise. Of note, the
majority of patients received ﬁrst-generation DES in the
included studies. The TVR rates ranged from as low as
4% to as high as 29% at 1 year, 6% to 34% at 2 years, 7% to
36% at 3 years, 12% to 23% at 4 years, and 11% to 28% at
5 years. In the PRECOMBAT 2 (Premier of Randomized
Comparison of Bypass Surgery Versus Angioplasty Using
Sirolimus-Eluting Stent in Patients With Left Main
Coronary Artery Disease) study (17) that compared the
second-generation everolimus-eluting stents to the historical
controls of the PRECOMBAT study on ﬁrst-generation
sirolimus-eluting stents, the rate of clinically driven TVR
was 3.4% versus 6% over 18 months. The current second-
generation stents with new stent platforms and superior
polymer and drug coating have been shown to have
increased beneﬁts in other lesions in head-to-head trials
and pooled analysis with ﬁrst-generation DES (18,19).
Therefore, with increasing use of second-generation DES,
we should expect a drop in TVR in future trials. The results
of the EXCEL (Evaluation of Xience Prime versus Coro-
nary Artery Bypass Surgery for Effectiveness of Left Main
Revascularization) trial (20) comparing the Xience Prime
stent (Abbott Vascular, Santa Clara, California) with
CABG for left main disease, therefore, are eagerly awaited in
this regard. Highest rates of TVR in the PCI arm were also
observed in studies with more distal left main disease
(Online Refs. e2,e10). This observation is well recognized
and has been linked to procedural complexity and multile-
sional stenting. In an Italian observational study on ostial
and mid-shaft lesions versus bifurcation lesions in 1,111
patients with UPLMS, Palmerini et al. (21) showed that the
2-year incidence of MACCE was signiﬁcantly higher in
patients with distal left main–bifurcation disease. On strat-
ifying bifurcation lesions according to the technique used,
patients treated with 2 stents had a signiﬁcantly higher
incidence of MACCE compared with patients with ostial
and mid-shaft lesions, whereas patients with bifurcation
lesions treated with 1 stent had a clinical outcome similar to
that of patients with ostial and mid-shaft lesions. In our
analysis, we could not make the distinction between single
stenting versus multiple stenting in distal lesions. In the
included studies, IVUS guidance for PCI was not routinely
performed. But in included studies that did use IVUS, there
was a trend towards lower rates of TVR. In thePRECOMBAT trial (Online Refs. e11), the usage of IVUS
was around 83%. This translated to a TVR of 6% at 1 year
and 9% at 2 years. In 201 matched pairs of the overall
population of the MAIN-COMPARE (revascularization
for unprotected left MAIN coronary artery stenosis:
COMparison of Percutaneous coronary Angioplasty versus
surgical REvascularization) registry, Park et al. (22) showed
a tendency of lower risk of 3-year morality with IVUS
guidance compared with angiography guidance (6.0% vs.
13.6%, log rank p ¼ 0.063; hazard ratio ¼ 0.54; 95% CI ¼
0.28 to 1.03). Despite evidence (23,24) in favor of IVUS
guidance to decrease stent thrombosis and restenosis, its
routine clinical use has not been widely accepted. We believe
that IVUS guidance during PCI of UPLMS is necessary to
optimize stent expansion and ensure full lesion coverage.
MACCE is a widely used endpoint in cardiovascular trials
to decrease sample size and increase power (25). However,
the use of MACCE is not without limitations. Despite
its frequent use, there is no standardized deﬁnition for
MACCE. Also, depending on the set of components
used to deﬁne MACCE, widely different results and
conclusions may be obtained (25). The individual compo-
nents of MACCE, with the exception of mortality, are not
uniformly deﬁned across studies, thereby limiting systematic
comparisons. Leonardi et al. (26) found that the deﬁnition
for MI was heterogeneous, and implementation of recent
consensus recommendations for deﬁning MI was also low in
a large number of contemporary RCTs in cardiovascular
disease. The interpretation of MACCE can be difﬁcult
when the individual components lack a directional consis-
tency, yet another limitation to the use of MACCE. We
therefore analyzed MACCE as a secondary endpoint,
contrary to other meta-analyses (13,14). Despite the trend
towards increased MI among PCI-treated patients, there
was no difference in MACCE, suggesting that the risk of
stroke with CABG is positive. The less sensitive deﬁnition
of MI (only Q-wave MI) used by the studies in the 5-year
analysis likely decreased the event counts of MI and tilted
the balance of MACCE in favor of PCI at 5 years in our
analysis. Nevertheless, the clinical signiﬁcance of interpret-
ing MACCE in this situation is questionable with stroke
and MI, 2 equally signiﬁcant clinical components being
affected in opposite directions.
Diabetic patients pose special challenges to percutaneous
therapy of coronary artery disease. Numerous clinical studies
(27–29) in the percutaneous transluminal coronary angio-
plasty and bare-metal stent era have shown that these
patients have accelerated restenosis, a need for repeat
revascularization, and an increased mortality at long-term
follow-up when treated with percutaneous techniques in
comparison with surgical revascularization. The heightened
risk of restenosis in these patients is primarily due to an
exaggerated intimal hyperplasia that causes decreased vessel
lumen area. DES have been shown to lower the incidence of
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coronary angioplasty or stenting with bare-metal stents in
diabetic patients (30). Despite the superiority of DES,
diabetes remained a signiﬁcant predictor of higher risk of
repeat revascularization after PCI with DES for UPLMS as
opposed to CABG at long-term follow-up (>2 years) in our
analysis. At short-term (1 to 2 years) follow-up, there was
no signiﬁcant interaction for the outcome of TVR between
PCI versus CABG and percentage of diabetic patients
enrolled. There was similarly no difference in mortality at
short-or long-term follow-up between the 2 treatments.
Our ﬁndings are similar to 2 large multicenter trials that
compared PCI with DES to surgical revascularization
in patients with multivessel disease (5,31). Both studies
showed comparable results between PCI with DES and
CABG at short-term follow-up; however, long-term follow-
up demonstrated superior results with surgical revascu-
larization. With few exceptions, CABG should therefore
remain the preferred treatment option in diabetic patients
with UPLMS.
The use of the angiographic SYNTAX score for patient
selection in UPLMS is conﬂicting. Our analysis of available
data, however, supports the idea that patients with a high
SYNTAX score may be better served with CABG. The
correlation of a high SYNTAX score to mortality may not
be perfect but likely identiﬁes a group of patients who may
not fare well with PCI. The results of the EXCEL trial (20)
comparing the Xience Prime stent with CABG for left main
disease in patients with low-to-intermediate SYNTAX
scores, therefore, are eagerly awaited.
Study limitations. Some of the limitations of this study are
those inherent to any meta-analysis: 1) inclusion of non-
randomized comparisons and very few randomized studies;
2) inclusion of nonrandomized comparisons introduced
heterogeneity in our analyses of certain outcomes; 3)
incomplete reporting and variable deﬁnitions of endpoints by
the primary studies may have introduced reporting and
detection bias; 4) incomplete reporting resulted in under-
powered analyses for certain outcomes during sensitivity
testing; 5) we could not adjust for confounding variables if
not reported by the primary studies; and 6) publication bias is
another inherent limitation of any meta-analyses.
Conclusions
From available all-comers data (RCT and real world), there
is no survival beneﬁt of CABG over PCI for UPLMS up to
5 years from the index procedure in the DES era. Further-
more, there is no difference in the safety endpoint of
MACCE during follow-up. There is a persistent risk of
stroke with CABG and of MI with PCI. Diabetes is
a predictor of increased TVR after PCI at long-term follow-
up. Patients with high angiographic SYNTAX scores may
have better outcomes with CABG. However, PCI withDES is a comparable alternative to CABG for patients with
low and intermediate SYNTAX scores. These results should
be taken into consideration when selecting revascularization
strategy for patients with severe left main stenosis.
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